GT Biopharma (GTBP)
NASDAQ:GTBP
Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.26 - $3.85
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$15.12M
Enterprise Value-$4.47M
Total Cash (Recent Filing)$8.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding36,062,904
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$3.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform DifferentiationGT Biopharma’s focus on NK cell–engaging biologics and TriKE-style engineered therapeutics represents a durable scientific differentiation. If clinical proof emerges, the platform can create a sustainable competitive advantage across multiple oncology indications and drive durable licensing or partnership interest.
Academic Trial PartnershipThe University of Minnesota-sponsored IND and three-year trial shifts substantive operational and regulatory burden to a reputable academic partner, validating the science and reducing some execution risk. This structured collaboration supports clinical de-risking and future external funding or industry partnerships.
Low LeverageMinimal debt gives the company financial flexibility and lowers near-term insolvency risk while it remains pre-revenue. Low leverage preserves options to raise capital via equity or partnerships without immediate debt servicing pressure, a material structural benefit for a development-stage biotech.
Bears Say
Pre-revenue LossesBeing pre-revenue with recurring, sizable net losses constrains GT Biopharma’s ability to self-fund development. The sustained negative profitability means the company will likely need external capital repeatedly, creating execution risk and potential dilution absent durable clinical or partnership milestones.
Consistent Cash BurnPersistent negative operating and free cash flow signal a structural funding need to sustain operations and trials. Ongoing cash burn shortens runway absent new financing or partnerships, increasing dependency on capital markets and raising the probability of dilutive financings that affect long-term shareholder value.
Very Small Operating ScaleAn extremely small internal team implies heavy reliance on CROs, academic partners, and external vendors for R&D and operations. This limits internal execution capacity, slows scalable commercialization planning, and increases operational dependency risks if partnerships or contractors underperform.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.26 and its highest was $3.85 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $15.12M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Aug 12, 2026 which is in 83 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on May 18, 2026. The company reported -$0.111 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.001.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 36,062,904 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.111 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -7.379%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
GTBP Stock 12 Month Forecast
Average Price Target
$3.00
▲(310.96% Upside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
2.37%
Insiders
0.10% Mutual Funds
0.61% Other Institutional Investors
95.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---